作者
Eva Mittler,Alexandra Serris,Emma S. Esterman,Catalina Florez,Laura Polanco,Cecilia M. O’Brien,Megan M. Slough,Janne Tynell,Remigius Gröning,Yan Sun,Dafna M. Abelson,Anna Z. Wec,Denise Haslwanter,Markus Keller,Chunyan Ye,Russel R. Bakken,Rohit K. Jangra,John M. Dye,Clas Ahlm,C. Garrett Rappazzo,Rainer G. Ulrich,Larry Zeitlin,James C. Geoghegan,Steven B. Bradfute,Simone Sidoli,Mattias N. E. Forsell,Tomas Strandin,F.A. Rey,Andrew S. Herbert,Laura M. Walker,Kartik Chandran,Pablo Guardado‐Calvo
摘要
Emerging rodent-borne hantaviruses cause severe diseases in humans with no approved vaccines or therapeutics. We recently isolated a monoclonal broadly neutralizing antibody (nAb) from a Puumala virus–experienced human donor. Here, we report its structure bound to its target, the Gn/Gc glycoprotein heterodimer comprising the viral fusion complex. The structure explains the broad activity of the nAb: It recognizes conserved Gc fusion loop sequences and the main chain of variable Gn sequences, thereby straddling the Gn/Gc heterodimer and locking it in its prefusion conformation. We show that the nAb’s accelerated dissociation from the divergent Andes virus Gn/Gc at endosomal acidic pH limits its potency against this highly lethal virus and correct this liability by engineering an optimized variant that sets a benchmark as a candidate pan-hantavirus therapeutic.